GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
GlobalRPh source record

Dofetilide (Tikosyn)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Tikosyn / Dofetilide

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Tikosyn - product and source limitations

Initiate or reinitiate with inpatient continuous ECG monitoring for at least three days. Follow the label's baseline and post-dose QT algorithm, interaction exclusions, and electrolyte checks.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Tikosyn - product and source limitations

Historical source

Original GlobalRPh source

Choose a product and source Tikosyn | Product label Tikosyn | GlobalRPh RX passage All evidence
Product / population
Preserved GlobalRPh source, not a freshly verified product label
Renal measure
Use the method specified in the original source
Source revision
Historical source; revision not established here
Retrieved
2026-09-05 (not the revision date)

Historical source: not automatically current. Review current official labeling and separately attributed additions before use.

The original QTc phrase >15% of baseline is ambiguous and is preserved rather than silently converted to a current-label algorithm. This excerpt alone is not the complete monitored initiation protocol.

Usual Dosing (Adults)

TIKOSYN is indicated to maintain normal sinus rhythm/delay recurrence in patients with AF/flutter lasting >1 week who have converted to sinus rhythm, and for conversion of AF/flutter. Because of life-threatening ventricular arrhythmias, reserve for highly symptomatic AF/flutter. Antiarrhythmic treatment aims to prolong sinus rhythm; recurrence is expected in some. It has not shown effectiveness for paroxysmal AF.

The source lists 500 micrograms orally twice daily initially, with lower doses at physician discretion and renal doses below. Measure QTc 2 to 3 hours after the first dose. The source wording is "If the QTc >15% of baseline, or if the QTc is >500 msec (550 msec in patients with ventricular conduction abnormalities), dofetilide should be adjusted." For inpatient doses 2 through 5, measure QTc 2 to 3 hours after each dose; stop if QTc >500 ms (550 ms with ventricular conduction abnormalities).

Renal Dosing

CrCl >60 mL/min: 500 micrograms twice daily; 40 to 60: 250 micrograms twice daily; 20 to 39: 125 micrograms twice daily; <20: contraindicated.

Hemodialysis

Contraindicated.

Source revision: Historical source; revision not established here | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://globalrph.com/renal/dofetilide/

Scope: Preserved historical source; no fresh clinical approval GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Tikosyn - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 30, posted Apr 22, 2026

Renal measure: Cockcroft-Gault CrCl with actual body weight, mL/min

Read this dated source finding
Rxlist

Tikosyn - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Tikosyn - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Tikosyn - product and source limitations

Initiate or reinitiate with inpatient continuous ECG monitoring for at least three days. Follow the label's baseline and post-dose QT algorithm, interaction exclusions, and electrolyte checks.

How to use this: Apply only to the stated formulation, indication and renal population.

Tikosyn - labeled renal guidanceTikosyn - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeTikosyn - labeled renal guidanceTikosyn - selected RX renal passage
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The original QTc phrase >15% of baseline is ambiguous and is preserved rather than silently converted to a current-label algorithm. This excerpt alone is not the complete monitored initiation protocol.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/dofetilide/

Usual Dosing (Adults)

TIKOSYN is indicated to maintain normal sinus rhythm/delay recurrence in patients with AF/flutter lasting >1 week who have converted to sinus rhythm, and for conversion of AF/flutter. Because of life-threatening ventricular arrhythmias, reserve for highly symptomatic AF/flutter. Antiarrhythmic treatment aims to prolong sinus rhythm; recurrence is expected in some. It has not shown effectiveness for paroxysmal AF.

The source lists 500 micrograms orally twice daily initially, with lower doses at physician discretion and renal doses below. Measure QTc 2 to 3 hours after the first dose. The source wording is "If the QTc >15% of baseline, or if the QTc is >500 msec (550 msec in patients with ventricular conduction abnormalities), dofetilide should be adjusted." For inpatient doses 2 through 5, measure QTc 2 to 3 hours after each dose; stop if QTc >500 ms (550 ms with ventricular conduction abnormalities).

GRPH-dofetilide-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

CrCl >60 mL/min: 500 micrograms twice daily; 40 to 60: 250 micrograms twice daily; 20 to 39: 125 micrograms twice daily; <20: contraindicated.

GRPH-dofetilide-02 · Source section: Renal DosingRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Tikosyn - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Dofetilide (Tikosyn), oral capsule

Renal method: Cockcroft-Gault CrCl with actual body weight, mL/min
Source date: DailyMed SPL version 30, posted Apr 22, 2026
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Dosage and Administration, individualized dose initiation steps 1-7

Limits that apply to these rows

Initiate or reinitiate with inpatient continuous ECG monitoring for at least three days. Follow the label's baseline and post-dose QT algorithm, interaction exclusions, and electrolyte checks.

Adult initial dosing after QT and eligibility checks
Calculated CrCl (mL/min)Initial oral regimen
>60500 mcg twice daily
40-60250 mcg twice daily
20 to <40125 mcg twice daily
<20Contraindicated
Read the retained text before reformatting

Initial oral doses by calculated CrCl are 500 mcg twice daily above 60, 250 mcg twice daily at 40-60, and 125 mcg twice daily at 20 to below 40 mL/min. Below 20, use is contraindicated. Initiate or reinitiate with inpatient continuous ECG monitoring for at least three days. Follow the label's baseline and post-dose QT algorithm, interaction exclusions, and electrolyte checks.

RDM74-tikosyn-official-1 · Source locator: Renal guidance: Dosage and Administration, individualized dose initiation steps 1-7

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02438044-d6a3-49e9-a1ac-3aad21ef2c8c
Retrieved
2026-11-07
Renal-function method
Cockcroft-Gault CrCl with actual body weight, mL/min
Source date/version
DailyMed SPL version 30, posted Apr 22, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
f61f189e9154fea5d01fea93eb8a5b9716d7ab83197d73c09fa3a4f5c824192d
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Tikosyn - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Dofetilide (Tikosyn), oral capsule

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror links clearance-based dosing to QT and ventricular arrhythmia risk and identifies CrCl below 20 as a contraindication.

RDM74-tikosyn-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/tikosyn-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
2cce7fcaa259e6a025613a300a8eb9b4c55c74de78bb8c2cadaad4559846a382

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/dofetilide/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
eeacd9573f0bc23318a31a5d561bb0572c5bdc9b396307edb6775527ebf160a0
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report
Top